The traditional Chinese medicine sector reappeared, and two stocks including Panlong Pharmaceutical Co., Ltd.

[Pharmaceutical Network Pharmaceutical Stock Market] On June 16th, there was another change in the traditional Chinese medicine sector, and the sector continued to ri.
As of the close, Dali Pharmaceuticals and Panlong Pharmaceuticals rose by their daily limit, Essence Pharmaceuticals rose by more than 6%, Xinbang Pharmaceuticals and Kanghui Pharmaceuticals rose by more than 5%, and Tongrentang and Guangyuyuan followed su.
The daily limit of two traditional Chinese medicine stocks Among them, Dali Pharmaceutical closed at 126 yuan, up more than 10%, with a turnover of 586 million, a turnover rate of 189%, and a TTM lo.
It is understood that the stock has risen by the limit 28 times in the past ye.
Regarding the reasons for the change, the analysis believes that the company's main products Xingnaojing injection and Shenmai injection are listed in the sixth, seventh, eighth and ninth editions of the National Health Commission and the State Administration of Traditional Chinese Medici.
Recommended medication for the Novel Coronavirus Pneumonia Diagnosis and Treatment Progr.
In addition, the Northeast Securities Research Report pointed out that in recent years, traditional Chinese medicine formula granules have shown a rapid growth tre.
Under the leading role of a series of policies and the trend of traditional Chinese medicine consumption upgrading, the penetration rate of traditional Chinese medicine formula granules is expected to continue to increa.
The report for the first quarter of 2022 shows that during the reporting period, the company achieved operating income of 39,816,7015 yuan, a year-on-year decrease of 174%; the net profit attributable to shareholders of the listed company was -3,207,5031 yuan, which turned from profit to loss compared with the same period last ye.

According to the data, Dali Pharmaceutical's main business is the production and sales of Chinese and Western medicine injectio.
The company's main products are "Zhongjing" Xingnaojing injection and Shenmai injecti.
Panlong Pharmaceuticals closed at 382 yuan today, an increase of 10%, with a turnover of 346 million, a turnover rate of 131%, and a price-earnings (TTM) of 31The stock has risen by the limit 18 times in the past ye.
Regarding the reasons for this stock price change, the analysis pointed out that the company's "Coronavirus 3CL Protease Inhibitor Development" project has been submitted to the "2021 Second Batch of Key Core Technology Industrialization" jointly issued by the Shaanxi Provincial Department of Industry and Information Technology and the Department of Finan.
Project", which has been selected into the project library and has submitted the materials for unveiling the li.
The 2021 annual report shows that the company achieved operating income of about 887 million yuan, a year-on-year increase of 34%; the net profit attributable to shareholders of the listed company was about 917 million yuan, a year-on-year increase of 17
According to the data, Panlong Pharmaceutical is an enterprise integrating GAP cultivation of medicinal materials, drug production, research and development, sales and pharmaceutical logistics as its core industri.
Top-level policies support the strategic position of traditional Chinese medicine On the news, top-level policies support the strategic position of traditional Chinese medici.
Recently, Shanghai, Tianjin, Anhui and other places have issued relevant policies to support the inheritance and development of traditional Chinese medici.
Among them, Shanghai proposes to encourage the application of Chinese medicine compound preparations derived from ancient classic prescriptions and preparations of medical institutions with long-term clinical efficacy verification; It is mentioned to promote the high-quality development of traditional Chinese medicine and the industry, and build a strong city of traditional Chinese medicine; Anhui released the "Anhui Province Action Plan for Promoting the Revitalization and Development of Traditional Chinese Medicine (2022-2024)", striving for the province's traditional Chinese medicine industry and traditional Chinese medicine health in three years The total output value of the service industry chain has reached 400 billion yu.
In general, whether at the national or local level, a series of favorable policies support traditional Chinese medicine, giving the industry a driving force for sustainable developme.
Wanlian Securities Research Report pointed out that top-level policies support the strategic position of traditional Chinese medici.
In recent years, policies have focused on medical insurance payment, review and approval and other directio.
Coupled with the gentle implementation of centralized procurement of proprietary Chinese medicines, companies are forced to pay attention to quality and innovati.
From 2021 to 2022, Hubei Alliance and Guangdong Alliance will implement centralized procurement of proprietary Chinese medicines, and the scope of centralized procurement will be expanded in the futu.
With the advancement of centralized procurement in the traditional Chinese medicine industry, traditional Chinese medicine companies need to strengthen investment in scientific research, academic and evidence-based medicine for new products, as well as the development of innovative drugs with clinical value, which will force the traditional Chinese medicine industry to develop in the direction of innovati.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
 Click to enter the exhibition page